Immunome is a clinical-stage biotechnology company focused on discovering and developing first-in-class targeted therapies for oncology, primarily using antibody-drug conjugate (ADC) technology, leveraging a proprietary, memory B cell-based discovery engine to identify novel antibodies that treat cancers. The company's strategy is centered on cell-surface-targeting agents and small molecules, with the ultimate goal to develop a targeted oncology platform that can overcome resistance and enable bystander activity.
Cyborg Score Rationale
The company delivered top-line Phase 3 results for Varegacestat in desmoid tumors and is in the process of filing a New Drug Application as it sets its sights on a $1 billion market opportunity. However, as a clinical-stage biotech, the company remains pre-commercial with significant development risk, balanced by a validated pipeline approach and recent regulatory progress.
Top Insights
Phase 3 positive results for Varegacestat in desmoid tumors with NDA filing underway, targeting a $1 billion market opportunity and plans to submit three additional INDs this year for solid tumor programs.
Company's radioligand therapy (IM-3050) receives FDA clearance and is poised to start clinical trials.
Advanced pipeline includes Varegacestat in Phase 3 for desmoid tumors and IM-1021 (ROR1-ADC) in Phase 1, with preclinical solid tumor ADC candidates in development.
Current market capitalization of $2.45B as of latest update.
Named Competitors
Antibody-Drug Conjugate Therapies — Established ADC developers with marketed or late-stage programs
Gamma Secretase Inhibitors — Companies developing alternative desmoid tumor and cancer therapeutics
Radioligand Therapies — Competitors in targeted radiation therapy space
Recent Developments
(February 2026) Immunome grants 30,000 inducement stock options to new employee at $26.14 exercise price
(December 2025) Announced positive topline Phase 3 results from RINGSIDE trial of Varegacestat in desmoid tumors
(December 2025) Completed public offering of common stock
(February 2026) CEO Clay Siegall reiterates focus on building oncology-focused pipeline with expanded strategic initiatives
Open the full interactive Immunome, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.